[go: up one dir, main page]

AR077819A1 - Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip) - Google Patents

Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)

Info

Publication number
AR077819A1
AR077819A1 ARP100102904A ARP100102904A AR077819A1 AR 077819 A1 AR077819 A1 AR 077819A1 AR P100102904 A ARP100102904 A AR P100102904A AR P100102904 A ARP100102904 A AR P100102904A AR 077819 A1 AR077819 A1 AR 077819A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
crdrd
haloalkyl
zero
Prior art date
Application number
ARP100102904A
Other languages
English (en)
Inventor
John L Gilmore
James E Sheppeck
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR077819A1 publication Critical patent/AR077819A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

También procedimientos de uso de dichos compuestos como agonistas selectivos para el receptor S1P1 acoplado a proteína G, y composiciones farmacéuticas que comprenden dichos compuestos. Estos compuestos son utiles en el tratamiento, la prevencion o la ralentizacion de la progresion de enfermedades o trastornos en una variedad de áreas terapéuticas, tales como enfermedades autoinmunitarias y enfermedad vascular. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) o un estereoisomero o una sal farmacéuticamente aceptable del mismo, en la que m es 1 o 2; n es 1 o 2; en la que W es CH2 cuando (m + n) es 2 o 3; o W es CH2, O, o NH cuando (m + n) es 4; R1 es -(CRdRd)aOH, -(CRdRd)aCOOH, -(CRdRd)aC(O)NRcRc, -(CRdRd)aC(O)NHS(O)2(alquilo C1-3), -(CRdRd)aC(O)NHS(O)2(arilo), o - (CRdRd)atetrazolilo; cada R2 es, de forma independiente, halo, aIquilo C1-4, haloalquilo C1-2, -OH, alcoxi C1-3 y/o -NRcRc; R3 y R4 son, de forma independiente, H y/o alquilo C1-6, o R3 y R4 junto con el átomo de carbono al que están unidos, forman un anillo de 3 a 6 miembros que contienen cero o 1 heteroátomo seleccionado de O y N; R5 es H o alquilo C1-4; cada R6 es, de forma independiente, alquilo C1-3, halo, haloalquilo C1-3, -CN, -OH, alcoxi C1-3 y/o haloalcoxi C1-3; A es como en formulas (2) a (5); Q es un grupo heteroarilo monocíclico de 5 miembros que tiene de 1 a 3 heteroátomos seleccionados, de forma independiente de N, O, y/o S, en la que dicho grupo heteroarilo está sustituido con Ra y cero o 1 Rb, y siempre que cuando A es como en formula (2), Q no es 2-furan-2-ilo, 4-tiazolilo, 4-oxazolilo o 1,2,3-triazolilo, Ra es alquilo C2-6, haloalquilo C2-4, cicloalquilo C3-6, tetrahidropiranilo, o un grupo cíclico seleccionado de fenilo, bencilo y grupos heteroarilo monocíclicos de 5 a 6 miembros que tienen de 1 a 3 heteroátomos seleccionados de forma independiente de N, O, y/o S, en el que dicho grupo cíclico está sustituido con cero, 1, 2 o 3 sustituyentes seleccionados, de forma independiente, de halo, -CN, -OH, alquilo C1-4, alcoxi C1-3haloalquilo y/o haloalcoxi C1-2; Rb es alquilo C1-3 o haloalquilo C1-3, siempre que si Ra es alquilo, Rb es haloalquilo C1-3; cada Rc es, de forma independiente, H y/o alquilo C1-4; cada Rd es, de forma independiente, H, -OH, alquilo C1-4, haloalquilo C1-4 y/o alcoxi C1-4; a es cero, 1, 2, o 3; t es cero, 1, 2, 3 o 4; y x es cero, 1 o 2; con la condicion de que se excluyen los compuestos de formulas(6).
ARP100102904A 2009-08-07 2010-08-06 Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip) AR077819A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23205409P 2009-08-07 2009-08-07

Publications (1)

Publication Number Publication Date
AR077819A1 true AR077819A1 (es) 2011-09-28

Family

ID=43029859

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102904A AR077819A1 (es) 2009-08-07 2010-08-06 Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)

Country Status (19)

Country Link
US (1) US8399451B2 (es)
EP (1) EP2462139B1 (es)
JP (1) JP5602230B2 (es)
KR (1) KR20120108963A (es)
CN (1) CN102548989A (es)
AR (1) AR077819A1 (es)
AU (1) AU2010279354A1 (es)
BR (1) BR112012002824A2 (es)
CA (1) CA2770194A1 (es)
CL (1) CL2012000326A1 (es)
CO (1) CO6430439A2 (es)
EA (1) EA201270266A1 (es)
ES (1) ES2533095T3 (es)
MX (1) MX2012001160A (es)
PE (1) PE20120732A1 (es)
SG (1) SG177691A1 (es)
TW (1) TW201109323A (es)
WO (1) WO2011017578A1 (es)
ZA (1) ZA201200641B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667545A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
CN103119038B (zh) * 2010-04-23 2016-05-04 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1,2,4-噁二唑基-3-基)扁桃酰胺
EP2595969B1 (en) 2010-07-20 2015-04-22 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
JP5869579B2 (ja) 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 置換オキサジアゾール化合物およびそれらのs1p1アゴニストとしての使用
WO2012061459A1 (en) * 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
AR101591A1 (es) 2014-08-20 2016-12-28 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos
UY38367A (es) * 2018-09-13 2020-04-30 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
CN114181276A (zh) * 2021-12-17 2022-03-15 安徽大学 硫酯肽合成方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS6480026A (en) 1987-09-21 1989-03-24 Mitsubishi Electric Corp Resist coater
DE4102024A1 (de) 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
EP0934265B1 (en) 1996-08-16 2003-01-02 Bristol-Myers Squibb Pharma Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
US7309721B2 (en) 2002-03-01 2007-12-18 Merck + Co., Inc. Aminoalkylphosphonates and related compounds as Edg receptor agonists
JP4669225B2 (ja) 2002-04-23 2011-04-13 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物
AU2003276043A1 (en) 2002-06-17 2003-12-31 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
US7220734B2 (en) 2002-12-20 2007-05-22 Merck & Co., Inc. 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as Edg receptor agonists
JP4505449B2 (ja) 2003-02-11 2010-07-21 アイアールエム・リミテッド・ライアビリティ・カンパニー 新規二環式化合物および組成物
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
JP4728962B2 (ja) 2003-05-19 2011-07-20 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
MXPA05012459A (es) 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresoras.
US20070043014A1 (en) * 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
CA2596990A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
SI1863474T1 (sl) 2005-03-23 2009-04-30 Actelion Pharmaceuticals Ltd Novi derivati tiofena kot agonisti receptorja sfingozin-1-fosfat-1
CA2602474C (en) 2005-03-23 2014-06-10 Actelion Pharmaceuticals Ltd Hydrogenated benzo (c) thiophene derivatives as immunomodulators
JPWO2006115188A1 (ja) 2005-04-22 2008-12-18 第一三共株式会社 ヘテロ環化合物
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
AU2006260573A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
AU2006283175A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
TW200800911A (en) 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
JP2009520688A (ja) 2005-11-23 2009-05-28 エピックス デラウェア, インコーポレイテッド S1p受容体調節化合物およびそれらの使用
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
WO2007109330A2 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1p receptor modulating compounds
JP5099005B2 (ja) 2006-04-03 2012-12-12 アステラス製薬株式会社 ヘテロ化合物
WO2008016674A1 (en) 2006-08-01 2008-02-07 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine- 1- phosphate receptor (slp)
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
JP2010504286A (ja) 2006-09-07 2010-02-12 アラーガン インコーポレイテッド スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物
AR062683A1 (es) 2006-09-07 2008-11-26 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
DK2069335T3 (da) 2006-09-08 2013-02-18 Actelion Pharmaceuticals Ltd Pyridin-3-ylderivater som immunomoduleringsmidler
BRPI0716598A2 (pt) 2006-09-08 2013-12-10 Novartis Ag Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos
EP2069318B1 (en) 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
JP2010504932A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー 抗炎症および免疫抑制特性を有するオキサジアゾール誘導体
JP2010510249A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン=1−燐酸アゴニスト活性を有するテトラリンアナログ
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
TW200838497A (en) 2006-12-21 2008-10-01 Abbott Lab Sphingosine-1-phosphate receptor agonist and antagonist compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
EP2125797B1 (en) 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
AU2008240773B2 (en) 2007-04-19 2013-10-03 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
BRPI0817597A2 (pt) 2007-10-04 2015-04-07 Merck Serono Sa Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos
WO2009043889A2 (en) 2007-10-04 2009-04-09 Merck Serono S.A. Oxadiazole derivatives
KR20100092473A (ko) 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
US8202856B2 (en) 2007-12-21 2012-06-19 Merck Serono Sa Triazole oxadiazoles derivatives
HUE025984T2 (hu) 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
WO2010041655A1 (ja) 2008-10-06 2010-04-15 昭和電工株式会社 触媒およびその製造方法ならびにその用途
US20100160369A1 (en) 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
KR101589332B1 (ko) 2008-12-05 2016-01-27 아스텔라스세이야쿠 가부시키가이샤 2h-크로멘 화합물 및 그의 유도체
CN102245602B (zh) 2008-12-18 2014-09-10 默克雪兰诺有限公司 用于治疗多发性硬化症的与恶二唑稠合的杂环衍生物
US20100168079A1 (en) 2008-12-23 2010-07-01 Daniela Angst Biaryl Benzylamine Derivatives
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2382212B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
CN102361868A (zh) 2009-01-23 2012-02-22 百时美施贵宝公司 作为1-磷酸-鞘氨醇激动剂的吡唑-1,2,4-噁二唑衍生物
WO2010085582A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP5669363B2 (ja) 2009-03-31 2015-02-12 昭和電工株式会社 樹脂組成物及びこれで処理された紙又は繊維加工品
WO2010113528A1 (en) 2009-04-03 2010-10-07 Panasonic Corporation Mobile communication method, mobile communication system, and corresponding apparatus

Also Published As

Publication number Publication date
TW201109323A (en) 2011-03-16
CO6430439A2 (es) 2012-04-30
SG177691A1 (en) 2012-02-28
EP2462139B1 (en) 2015-01-14
BR112012002824A2 (pt) 2019-09-24
JP5602230B2 (ja) 2014-10-08
KR20120108963A (ko) 2012-10-05
EA201270266A1 (ru) 2012-07-30
WO2011017578A1 (en) 2011-02-10
CA2770194A1 (en) 2011-02-10
ES2533095T3 (es) 2015-04-07
PE20120732A1 (es) 2012-06-20
US8399451B2 (en) 2013-03-19
EP2462139A1 (en) 2012-06-13
AU2010279354A1 (en) 2012-02-09
JP2013501729A (ja) 2013-01-17
US20110190255A1 (en) 2011-08-04
CL2012000326A1 (es) 2012-10-19
MX2012001160A (es) 2012-02-13
CN102548989A (zh) 2012-07-04
ZA201200641B (en) 2013-06-26

Similar Documents

Publication Publication Date Title
AR077819A1 (es) Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
AR074089A1 (es) Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2
RU2016135922A (ru) Терапевтические соединения и композиции
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
AR085149A1 (es) Moduladores del receptor de glucagon
RU2013138372A (ru) Производные азетидина, применяемые для лечения метаболических и воспалительных заболеваний
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
AR083760A1 (es) Agentes antibacterianos y composiciones farmaceuticas
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
AR065804A1 (es) Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
PE20070172A1 (es) DERIVADOS BICICLICOS COMO INHIBIDORES DE p38
PE20080856A1 (es) Inhibidores de metaloproteasas de matriz
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
MY161403A (en) 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators
AR083832A1 (es) DERIVADOS DE TETRAHIDROPIRIDO[3,2-F][1,4]OXAZEPIN-8-AMINA PARA EL TRATAMIENTO DE ENFERMEDADES Ab-RELACIONADAS
PE20140629A1 (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos
EA201391538A1 (ru) Производные пиразолидин-3-она
PH12014500497A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulator
JP2015522556A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal